Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Insulin Icodec in Chinese Patients with Type 2 Diabetes
NCT04857398Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Apr 2021
- Primary completion
- Apr 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of insulin icodec in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Primary endpoint: Area under the serum insulin icodec concentration-time curve. Started Apr 2021; status: completed.
02
Drugs
insulin icodec
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04857398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04857398.